TAMMY HAM
Chief Executive Officer
As CEO of CicloMed LLC, Ms. Ham leads a team of experts committed to developing and commercializing an innovative, less-invasive approach to fighting bladder cancer. Since 2015 she has served as President of CicloMed’s parent company, BioNovus Innovations LLC, which is building a portfolio of organizations to advance scientific discoveries into transformational improvements in healthcare. Ms. Ham started her career as a Registered Nurse in hospitals and outpatient settings, then became a clinical administrator. In 1997, she founded Ambulatory Surgery Assistance, Inc., which developed about 30 ambulatory surgery centers for endoscopy. After selling that company to Nueterra Healthcare in 2005, Ms. Ham served in increasingly responsible executive roles with Nueterra. She is a graduate of Saint Luke’s College of Nursing <and the University of Missouri-Kansas City?>. Ms. Ham also serves as a mentor with Techstars and a board member of Operation Breakthrough.
William McCulloch, M.B., Ch.B., F.R.C.P., F.F.P.M.
Chief Medical Officer and member of Scientific Advisory Board
Dr. McCulloch brings to his role as CicloMed’s Chief Medical Officer more than three decades of experience in pharmaceutical research and development, as an executive and consultant to large and small companies focusing on cancer and serious infectious diseases. He has undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, securing Orphan Drug status for compounds, and obtaining SBIR and other grant funding. As co-founder and president of Alba BioPharm Advisors since 2002, Dr. McCulloch has provided consulting services in drug development, oncology and regulatory affairs for clients. He earned his medical degree at the University of Glasgow and practiced medicine in the United Kingdom for seven years before entering industry.
Scott J. Weir, Pharm.D., Ph.D.
Acting Chief Scientific Officer
Dr. Weir brings more than 30 years of pharmaceutical development experience to CicloMed. He is a professor at the University of Kansas Medical Center, Director of the Institute for Advancing Medical Innovation (IAMI) at KU, and Associate Director of Translational Research for the University of Kansas Cancer Center. He is a co-discoverer of Ciclopirox Prodrug, the anti-cancer agent that CicloMed is developing. Since joining KU in 2006, Dr. Weir has established and managed a fully integrated program to advance potential new drugs discovered at the University from bench to bedside. From 1986 to 2006, Dr. Weir served in leadership positions in a global pharmaceutical company and then a global contract research organization, contributing to successful development and regulatory approvals for a number of drugs. He earned his Pharm.D. degree from the University of Nebraska College of Pharmacy, followed by a Ph.D. in pharmacokinetics and biopharmaceutics from the University of Nebraska Medical Center.
Robyn Wood, B.G.S.
Project Manager
Ms. Wood has over 30 years of drug development experience and has worked since 2009 as project director for the Institute for Advancing Medical Innovation (IAMI) at The University of Kansas Medical Center. A University of Kansas alumna, she spent 17 years with INTERx Research/Merck as a Research Biologist, later moving to Oread Pharmaceuticals and Quintiles. At Quintiles, Ms. Wood was hired as the first project manager to support drug development projects and while there she moved into a senior director position. When Aptuit acquired the early drug development business of Quintiles, she moved from director of pharmaceutical services project manager to global director of client services for Aptuit.
John A. Taylor III, M.D., M.C.T.S.
Chief Scientific Advisor
Dr. Taylor is a board-certified urologist and nationally recognized expert on bladder cancer. His work has been recognized by multiple peer-reviewed publications and several U.S. provisional/full patents. He joined the University of Kansas Medical Center in 2016 and serves as a Professor, Director of Basic Urologic Research and Co-Leader of the D3ET Program. Dr. Taylor also founded and serves as President and Director of the Leo & Anne Albert Institute for Bladder Cancer Care and Research. He earned his medical degree at Columbia University’s College of Physicians & Surgeons, where he also completed his internship and residency in general surgery and urology. He served three years on active duty at Walter Reed Army Medical Center and was Director of Medical Education for Urology and Assistant Professor at USUHS. Dr. Taylor then took a faculty position at the University of Connecticut Health Center, and while there completed a Master’s in Clinical and Translation Science.
Robert Rogers
The following is placeholder text known as “lorem ipsum,” which is scrambled Latin used by designers to mimic real copy. Donec ac fringilla turpis. Donec ac fringilla turpis. Quisque congue porttitor ullamcorper.
Howard A. "Skip" Burris, III, M.D.
Principal Investigator and member of Scientific Advisory Board
As President of Clinical Operations and Chief Medical Officer of the Sarah Cannon Cancer Institute, HCA’s global cancer care and research organization, Dr. Burris leads clinical strategy and drug development initiatives, including overseeing physician-led, patient-centric integrated cancer care. He is serving as Principal Investigator for the Phase I clinical trial of Ciclopirox Prodrug. Dr. Burris has been elected President of the American Society of Clinical Oncology (ASCO) for the 2019-2020 term. He has served on many ASCO committees and boards and was honored by ASCO in 2014 as a “Giant of Cancer Care.” Dr. Burris practices medicine with Tennessee Oncology, PLLC. He has authored more than 350 publications and more than 550 abstracts. He earned his medical degree from the University of South Alabama and performed his residency and fellowship in hematology/oncology at Brooke Army Medical Center.